Skip to main
OKUR
OKUR logo

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc reported a net loss of $1.14 per share for the second quarter of 2025, which was an improvement compared to the initial loss estimate of $1.22 per share, indicating a narrowing of losses and potential operational efficiency gains. The company's lead candidate, OKI-219, demonstrated favorable safety profiles across all dose levels, with no instances of hyperglycemia and only mild treatment-related adverse events reported, suggesting a strong potential for further clinical development. Overall, OnKure's focus on precision medicines targeting underserved cancer treatments and the positive data surrounding OKI-219 may position the company favorably in the competitive biopharmaceutical landscape.

Bears say

OnKure Therapeutics Inc. is projected to incur a full-year net loss of $4.56 per share for 2025, which reflects a slight improvement from a previous estimate of $4.75 per share but still indicates significant financial challenges ahead. The company faces multiple risks that could impair its financial performance, including negative clinical results with its lead asset, OKI-219, potential delays in advancing pipeline candidates, and difficulties in obtaining timely regulatory approvals. Additionally, competitive pressures from other mutant-selective PI3Kα inhibitors and the risk of long-term dilution further compound the negative outlook for the stock.

OKUR has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Strong Buy based on their latest research and market trends.

According to 3 analysts, OKUR has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.